Cargando…

Indirect Treatment Comparison of Liso-Cel vs. Salvage Chemotherapy in Diffuse Large B-Cell Lymphoma: TRANSCEND vs. SCHOLAR-1

Most patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) have exhausted their treatment options and are deemed palliative. CD19-directed chimeric antigen receptor (CAR) T-cell therapy has recently been introduced as a new option for these patients. Lisocabtagene maraleucel...

Descripción completa

Detalles Bibliográficos
Autores principales:	Salles, Gilles, Spin, Paul, Liu, Fei Fei, Garcia, Jacob, Kim, Yeonhee, Hasskarl, Jens
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8189990/ https://www.ncbi.nlm.nih.gov/pubmed/33970454 http://dx.doi.org/10.1007/s12325-021-01756-0

Ejemplares similares

Matching-adjusted indirect treatment comparison of liso-cel versus axi-cel in relapsed or refractory large B cell lymphoma
por: Maloney, David G., et al.
Publicado: (2021)

Comparative effectiveness of ZUMA-5 (axi-cel) vs SCHOLAR-5 external control in relapsed/refractory follicular lymphoma
por: Ghione, Paola, et al.
Publicado: (2022)

P1154: EFFICACY OF SUBCUTANEOUS EPCORITAMAB VS AXI-CEL IN R/R DLBCL CAR T-NAIVE AND CAR T-ELIGIBLE PATIENTS: AN INDIRECT COMPARISON
por: Thieblemont, Catherine, et al.
Publicado: (2023)

Alzheimer's “Prevention” vs. “Risk Reduction”: Transcending Semantics for Clinical Practice
por: Hodes, John F., et al.
Publicado: (2019)

P1710: LISOCABTAGENE MARALEUCEL (LISO-CEL) AS SECOND-LINE TREATMENT FOR R/R LARGE B-CELL LYMPHOMA (LBCL) IN PATIENTS NOT INTENDED FOR HSCT: PATIENT-REPORTED OUTCOMES (PRO) FROM THE PHASE 2 PILOT STUDY
por: Gordon, L. I., et al.
Publicado: (2022)

Les normes de gestion de réseau à l'ISO
por: Lecerf, Christian, et al.
Publicado: (1993)

Transcending the self to transcend suffering
por: Ge, Brian H., et al.
Publicado: (2023)

Matching-adjusted indirect treatment comparison of chimeric antigen receptor T-cell therapies for third-line or later treatment of relapsed or refractory large B-cell lymphoma: lisocabtagene maraleucel versus tisagenlecleucel
por: Cartron, Guillaume, et al.
Publicado: (2022)

Direct vs. indirect detection of WIMPs
por: Rich, J, et al.
Publicado: (1995)

Etiology: Direct vs. Indirect Theories
Publicado: (1917)

From Self-Transcendence to Collective Transcendence: In Search of the Order of Hierarchies in Maslow’s Transcendence
por: Llanos, Luis Felipe, et al.
Publicado: (2022)

Indirect comparison of tisagenlecleucel and historical treatments for relapsed/refractory diffuse large B-cell lymphoma
por: Maziarz, Richard T., et al.
Publicado: (2022)

Transcending Conventional Biometry Frontiers: Diffusive Dynamics PPG Biometry
por: de Pedro-Carracedo, Javier, et al.
Publicado: (2021)

Nombres transcendants
por: Waldschmidt, Michel
Publicado: (1974)

Mar cel Levi
por: Baltesen, Frits
Publicado: (2021)

The use of tafasitamab in diffuse large B-cell lymphoma
por: Düll, Johannes, et al.
Publicado: (2021)

Direct vs. indirect sinus lift procedure: A comparison
por: Pal, U. S., et al.
Publicado: (2012)

Elliptic functions and transcendence
por: Masser, D W
Publicado: (1975)

Mahler functions and transcendence
por: Nishioka, Kumiko
Publicado: (1996)

Efficacy and safety of CD19‐directed CAR‐T cell therapies in patients with relapsed/refractory aggressive B‐cell lymphomas: Observations from the JULIET, ZUMA‐1, and TRANSCEND trials
por: Westin, Jason R., et al.
Publicado: (2021)

Comparison of 2-year outcomes with CAR T cells (ZUMA-1) vs salvage chemotherapy in refractory large B-cell lymphoma
por: Neelapu, Sattva S., et al.
Publicado: (2021)

Response to ifosfamide, carboplatin, etoposide (ICE) vs. dexamethasone, cytarabine cisplatin (DHAP) as salvage chemotherapy in patients with relapsed/refractory lymphoma
por: Devi, Kanta, et al.
Publicado: (2023)

UNILATERAL VS. DIFFUSE CHRONIC RHINOSINUSITIS
por: Vrljičak, Antonela, et al.
Publicado: (2022)

Transcending CSS : the fine art of web design
por: Clarke, Andy, 1965-
Publicado: (2007)

Imatinib and dasatinib as salvage therapy for sclerotic chronic graft-vs-host disease
por: Sánchez-Ortega, Isabel, et al.
Publicado: (2016)

Polytetrafluorethylene (PTFE) vs. Polyester (Dacron(®)) Grafts in Critical Limb Ischemia Salvage
por: Russu, Eliza, et al.
Publicado: (2023)

Pathogenic Carboxyl Ester Lipase (CEL) Variants Interact with the Normal CEL Protein in Pancreatic Cells
por: Dalva, Monica, et al.
Publicado: (2020)

Healthcare and Indirect Cost of the Laparoscopic vs. Vaginal Approach in Benign Hysterectomy
por: Martínez-Maestre, María Ángeles, et al.
Publicado: (2022)

Diffuse large B-cell lymphoma: new targets and novel therapies
por: Cheson, Bruce D., et al.
Publicado: (2021)

Olaparib: Transcending mutational barriers
por: Chandna, Abhishek
Publicado: (2019)

Shouldn’t Confidentiality Transcend Death?
por: Suhas, Satish
Publicado: (2020)

The Essence and Transcendence of Scientific Publishing
por: Medina-Franco, José L., et al.
Publicado: (2022)

Clearing the Pathways to Self-Transcendence
por: Worth, Piers, et al.
Publicado: (2021)

Computational Transcendence: Responsibility and agency
por: Deshmukh, Jayati, et al.
Publicado: (2022)

Efficacy comparison of tisagenlecleucel vs usual care in patients with relapsed or refractory follicular lymphoma
por: Salles, Gilles, et al.
Publicado: (2022)

Oncological Outcomes of Primary vs. Salvage OPHL Type II: A Systematic Review
por: Saraniti, Carmelo, et al.
Publicado: (2022)

Clinical Response to CHOP vs. R-CHOP in Adult Patients with Diffuse Large B-Cell Lymphomas
por: Tariq, Ayesha, et al.
Publicado: (2018)

Tafasitamab for the treatment of relapsed or refractory diffuse large B-cell lymphoma
por: Salles, Gilles, et al.
Publicado: (2021)

Efficacy of salvage radiotherapy for relapsed/refractory diffuse large B-cell lymphoma
por: Wang, Shu-Bei, et al.
Publicado: (2019)

Expression, Characterization and Synergistic Interactions of Myxobacter Sp. AL-1 Cel9 and Cel48 Glycosyl Hydrolases
por: Ramírez-Ramírez, Norma, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_elrof2ka8qprk7c5om71j2olq8